A case of influenza A and COVID-19 co-infection in a patient with severe asthma: Similarities and differences between the two viruses
More details
Hide details
2nd Pulmonary Medicine Department, School of Medicine, National and Kapodistrian University of Athens, "Attikon" University Hospital, Haidari, Greece
4th Department of Internal Medicine, School of Medicine, National and Kapodistrian University of Athens, "Attikon" University Hospital, Haidari, Greece
Ioannis Tomos   

"University Hospital "Attikon", Medical School, National and Kapodistrian University of Athens, Greece, 1 Rimini Street, 12462, Haidari, Greece
Publication date: 2021-08-31
Pneumon 2020;33(4):1–5
A novel coronavirus, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), resulting in an acute respiratory illness has been recently emerged to a pandemic. COVID-19 pandemic developed in a season when influenza was prevalent. Influenza is well known to cause respiratory infection with other respiratory pathogens, however, limited data exists concerning COVID-19 and influenza co-infection. Both viruses seem to share transmission characteristics and clinical manifestations. Asthma, on the other hand, a chronic inflammatory condition involving the airways seems to be a risk factor for severe COVID-19 illness. It is important for pulmonologists to be aware of such potential co-infections in order to be able to early recognize them and prevent disease progression and death. We report the case of a patient with severe asthma, receiving biologic treatment, with a history of a recent travel abroad, who presented co-infection of influenza A and SARS-COV-2, reviewing as well the literature concerning the similarities and differences between the two viruses.
The authors declare no funding sources.
Country & technical guidance – coronavirus disease (COVID-19) [website]. Geneva: World Health Organization; 2020 (
2. [website]. Data last updated: 2020/8/1.
Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395:507-13.
Zervas E, Samitas K, Papaioannou AI, Bakakos P, Loukides S, Gaga M. An algorithmic approach for the treatment of severe uncontrolled asthma. ERJ Open Res 2018;4:00125-2017.
Emma R, Morjaria JB, Fuochi V, Polosa R, Caruso M. Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience. Ther Adv Respir Dis 2018;12:1753466618808490.
Spanakis M, Zoumpoulakis M, Patelarou A, Patelarou E, Tzanakis N. COVID-19 epidemic: Comparison of three European countries with different outcome using Gompertz function method. Pneumon; 2020, 33:1-6.
Antoniou K, Bolaki M, Bibaki E, Vasarmidi E, Trachalaki A, Tsitoura E, Bouros D. COVID19 alert Do we know our enemy? Pneumon 2020, 33:25-27.
Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020;8:475-81.
Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. Vital surveillances: the epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) – China. China CDC Weekly 2020;2:113-22.
Burke RM, Midgley CM, Dratch A, et al. Active monitoring of persons exposed to patients with confirmed COVID19 — United States, January–February 2020. MMWR Morb Mortal Wkly Rep 2020.
Ong SWX, Tan YK, Chia PY, et al. Air, Surface Environmental, and Personal Protective Equipment Contamination by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) From a Symptomatic Patient. JAMA 2020;323:1610-2.
Lauer SA, Grantz KH, Bi Q, et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Ann Intern Med. 2020;172: 577-82.
Liu Y, Yan LM, Wan L, et al. Viral dynamics in mild and severe cases of COVID-19. Lancet Infect Dis 2020;20:656-7.
Ding Q, Lu P, Fan Y, Xia Y, Liu M. The clinical characteristics of pneumonia patients coinfected with 2019 novel coronavirus and influenza virus in Wuhan, China. J Med Virol 2020:10.1002/ jmv.25781.
Alqahtani JS, Oyelade T, Aldhahir AM, et al. Prevalence, Severity and Mortality Associated with COPD and Smoking in Patients with COVID-19: A Rapid Systematic Review and Meta-Analysis. PLoS One 2020;15:e0233147.
Tobacco use and COVID-19. 11 May 2020 Statement. Geneva: World Health Organization; 2020 (, accessed14 May 2020).
Williamson EJ, Walker AJ, Bhaskaran K, et al. OpenSAFELY: factors associated with COVID-19 death in 17 million patients. Nature. 2020;584:430-6.
Guan WJ, Ni ZY, Hu Y, et al., China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382:1708-20.
Rawson TM, Moore LSP, Zhu N, et al. Bacterial and fungal coinfection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing. Clin Infect Dis. 2020; ciaa530.